Navigation Links
AMRI Announces Fourth Quarter 2012 Adjusted EPS of $0.17
Date:2/12/2013

p>® and the OTC conversion of Allegra® on the company's receipt of significant royalties under the Allegra® license agreement; the success of the sales of other products for which the Company receives royalties; the over-the-counter sale of Claritin, and competitive alternatives, including generic products for the treatment of allergies and the risk of new product introductions for the treatment of allergies including generic forms of Allegra®; the risk that the company will not be able to replicate either in the short or long term the revenue stream that has been derived from the royalties payable under the Allegra® license agreements; the success of the company's collaborations with customers including the collaboration with Bristol-Myers Squibb Company related to biogenic amine reuptake inhibitors; the risk that clients may terminate or reduce demand under any strategic or multi-year deal; the company's ability to enforce its intellectual property and technology rights; the company's ability to obtain financing sufficient to meet its business needs and to meet the covenants set forth in its agreements or to negotiate a waiver or amendment with its lenders; the company's ability to successfully partner or out-license novel compounds and lead candidates in its collaborative arrangements; the company's ability to successfully comply with heightened FDA scrutiny on aseptic fill/finish operations; the company's ability to integrate the acquisitions closed during 2010 and make such acquisitions accretive to the company's business model, the company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company's strategic investments and acquisitions to perform as expected, as well as those risks discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Co
'/>"/>
SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Quantum Materials Corporation Announces Non-Heavy Metal (Cadmium-Free) Tetrapod Quantum Dots
2. The In View Series Announces Plans for a New Series on 3D-Printing
3. Elsevier Announces the Launch of a New Journal: Journal of Forensic Radiology and Imaging
4. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
5. Murray Test Prep Announces the Launch of their Online Tutoring Services
6. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
7. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
8. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
9. DNA Genotek Inc. Announces $10,000 GenoFIND™ Genomic Services Award
10. Spectrum Announces bioWorld Distribution Agreement
11. Life Technologies Announces Fourth Quarter and Fiscal 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Leading Regenerative Veterinary ... its allogeneic stem-cell product development program and changes ... the corporate strategic direction. , “I am extremely ... stem cell development program has been kicked into ... manufacturing facility and hiring of our new Director ...
(Date:4/24/2015)... PRINCETON, N.J. , April 24, 2015  Navitas Life ... Kumar as Head of Clinical and Regulatory Services. Shalabh ... having been a co-founder and CEO of Kinapse, as well ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
(Date:4/23/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology and medical device ... and the United States , today ... first quarter of 2015 after the New York Stock ... be Thursday morning, May 14, 2015 Shanghai time). The ...
Breaking Biology Technology:Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... by Novartis to evaluate safety and efficacy of Albuferon ... patients with genotypes 2 and 3 hepatitis C -ROCKVILLE, ... HGSI ) today announced that Novartis has ... evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) ...
... 12 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer ... today announced preliminary revenue,and earnings for the full ... Based upon preliminary data for the fourth quarter, ...
... Pharmaceuticals, a pioneer in the development of novel products ... disease, announced that Ted Hibben has joined the company ... from Coley Pharmaceutical Group, where he was most recently ... played a key role in the company,s $233 million ...
Cached Biology Technology:Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 2Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 4Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 5Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings 2Cequent Names Ted Hibben Chief Business Officer 2Cequent Names Ted Hibben Chief Business Officer 3
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... scientific conditions and measures, Johns Hopkins researchers have ... can induce mystical/spiritual experiences descriptively identical to spontaneous ... The resulting experiences apparently prompt positive changes in ... least. , The agent, a plant alkaloid ...
... on Long Island have identified which among several different kinds ... the widely prescribed antidepressant Prozac. This discovery might enable a ... side effects, to be developed. , The findings also lay ... how, when, and where new neurons are generated from stem ...
... for the first time that embryonic stem (ES) cells ... capacity to produce viable offspring. The research, published in ... avenues for future studies, including investigation of mechanisms involved ... for infertility. , Previous studies have shown that ES ...
Cached Biology News:Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 2Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 3Hopkins scientists show hallucinogen in mushrooms creates universal 'mystical' experience 4Prozac's target revealed 2Sperm created in the laboratory from embryonic stem cells produce viable progeny 2
Yersinia pestis...
... The features we add to WinList come ... product every day. Features like automatic region ... the result of good suggestions, thoughtful conversations, ... the features you depend on are still ...
Insect Cell Lysis Buffer 50 ml...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Biology Products: